A novel mRNA vaccine, SYS6006, against SARS-CoV-2.

ABSTRACT: The development of vaccines that can efficiently prevent the infection of SARS-CoV-2 is necessary to fight the COVID-19 epidemic. mRNA vaccine has been proven to induce strong humoral and cellular immunity against SARS-CoV-2. Here, we studied the immunogenicity and protection efficacy of a novel mRNA vaccine SYS6006. High expression of mRNA molecules in 293T cells was detected. The initial and boost immunization with a 21-day interval was determined as an optimal strategy for SYS6006. Two rounds of immunization with SYS6006 were able to induce the neutralizing antibodies against the SARS-CoV-2 wild-type (WT) strain, and Delta and Omicron BA.2 variants in mice or non-human primates (NHPs). A3^rd round of vaccination could further enhance the titers of neutralization against Delta

SUBMITTER: Xu K 

PROVIDER: S-EPMC9849951 | biostudies-literature | 2022

REPOSITORIES: biostudies-literature